Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

UK market access

- PMLiVE

Pharma demands guarantees for UK sector deal

Ten companies warn of Brexit threat, and long-standing flaws in medicines access

- PMLiVE

May earmarks £20bn for the NHS – but experts say it’s not enough

But claims of a “Brexit dividend” are rubbished

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

All the latest from the frontlines of healthcare

- PMLiVE

Keytruda cleared for frontline lung cancer in England – but only after another pricing deal

Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test

- PMLiVE

Daily Brief: GDPR and NHS Opt Out Day, BioMarin’s new rare disease approval and more

It's not just the GDPR's big day, plus news from Medigene and Pfizer

- PMLiVE

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

A rapid round up from the frontline of pharma, biotech and healthcare

- PMLiVE

NHS seeks ‘solution creators’ from within pharma

Health service is moving to a 'new era' of industry relations, says NHS England

- PMLiVE

Judge forces NHS England rethink on Kuvan

The health service claims the drug is not clinically effective

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

How will child public health be prioritised? by Alison Wall

Public health strategist Alison Wall stresses the importance of child public health as a commissioning responsibility.

Say Communications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links